{{Infobox drug
| drug_name         = 
| IUPAC_name        = 
| image             = 
| alt               = 
| caption           = 
<!-- Clinical data -->
| tradename         = ReFacto
| Drugs.com         = {{Drugs.com|UK|refacto-af}}
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = Rx-only
| routes_of_administration = 
<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
<!-- Identifiers -->
| CAS_number        = 
| ATCvet            = 
| ATC_prefix        = B02
| ATC_suffix        = BD02
| PubChem           = 
| DrugBank          = 
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula  = 
| molecular_weight = 170 kg/mol
}}
'''Moroctocog alfa''' (trade name '''ReFacto''') is a recombinant [[antihemophilic factor]] genetically engineered from [[Chinese hamster ovary]] (CHO) cell line. Chemically it is a [[glycoprotein]].<ref>http://www.abopharmaceuticals.com/ProductSheets/Refacto.pdf</ref> It is manufactured by [[Genetics Institute, Inc.]] and used to control and prevent hemorrhagic bleeding and prophylaxis associated with surgery or to reduce the number of spontaneous bleeding episodes in patients with [[hemophilia A]]. It is partially a recombinant coagulation [[factor VIII]] since it has an amino acid sequence which compares to the 90 + 80 kDa form of factor VIII (BDDrFVIII).<ref>{{cite web|url=http://www.ema.europa.eu/humandocs/PDFs/EPAR/Refacto/058999en6.pdf |accessdate=March 8, 2010 |deadurl=yes |archiveurl=https://web.archive.org/web/20100531074853/http://www.ema.europa.eu/humandocs/PDFs/EPAR/Refacto/058999en6.pdf |archivedate=May 31, 2010 }}</ref> It also has [[posttranslational modification]]s which are similar to those of the plasma-derived molecule. It can not prevent hemorrhagic bleeding associated with [[von Willebrand's disease]] since it is not a [[von Willebrand factor]].

==References==
{{reflist}}

{{Antihemorrhagics}}

[[Category:Recombinant proteins]]


{{blood-drug-stub}}